Exelon helps Alzheimer's disease patients to maintain greater independence

April 03, 2003 01:30 ET | Source: Novartis Pharma AG Novartis Pharma AG

Exelon® helps Alzheimer's disease patients to maintain greater independence

New findings suggest Exelon® significantly reduces decline in performance of activities of daily living in moderate to moderately severe Alzheimer's disease

Basel, 3 April 2003 - Therapy with Exelon (rivastigmine) helps patients with moderate to moderately severe Alzheimer's disease (AD) to maintain greater independence, according to an analysis of nearly 1500 patients.

Please find press release under the following link

Attachments

Media Release...

Recommended Reading

September 04, 2026 16:30 ET | Source: Novartis Pharma AG

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not...
Read More
September 01, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing...
Read More